EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Prognostic and Immune Infiltration Analysis of RBM4 in Pan-Cancer

Jia-Jun Ding, Jie Wu, Hai-Lei Bian, Yi Zong, Bing Lu, Li Ni

Frontiers in Bioscience-Landmark · 23.02.2024 · 29 (2)

DOI: 10.31083/j.fbl2902089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 23.02.2024. Verfasst von Jia-Jun Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Operating Room, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China. Hauptthemen laut MEDLINE: Alternative Splicing, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aberrant splicing has been closely associated with human cancer, though the precise underlying mechanisms linking the two remain not fully understood. Investigating the role of splicing factors in cancer progression may aid in the development of targeted therapies for dysregulated splicing, thereby opening up new avenues for cancer treatment. RNA-binding motif 4 (RBM4) has been identified as a critical participant in the condensin II complex, which is involved in chromosome condensation and stabilization during mitosis. Its significance in tumors is currently gaining attention. The genetic characteristics of RBM4 suggest its potential to elucidate the malignant progression of tumors in a broader context, encompassing various types of cancer, known as pan-cancer.

Methods

This study aims to comprehensively explore the potential function of RBM4 in pan-cancer by leveraging existing databases such as The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx).

Results

RBM4 is found to be overexpressed in almost all tumors and exhibits significant prognostic and diagnostic efficacy. The correlation between RBM4 and immune signatures, including immune cell infiltration and immune checkpoint genes, indicates that RBM4 could serve as a guiding factor for immunotherapy.

Conclusions

As a member of the pan-oncogene, RBM4 has the potential to become a biomarker and therapeutic target for various malignant tumors, offering novel possibilities for precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alternative SplicingNeoplasmsHumansPrognosisRNA SplicingRNA-Binding MotifsRNA-Binding Proteins

Stichwörter der Autor:innen

RBM4immune infiltrationpan-cancerprognosis

Substanzen

RBM4 protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Operating Room, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
  • Department of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
  • Department of Nursing, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 200127 Shanghai, China.
  • Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
  • Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.

Zitieren

APA

Ding, J. J., Wu, J., Bian, H. L., Zong, Y., Lu, B., & Ni, L. (2024). A Comprehensive Prognostic and Immune Infiltration Analysis of RBM4 in Pan-Cancer. Frontiers in Bioscience-Landmark, 29(2). https://doi.org/10.31083/j.fbl2902089

Vancouver

Ding JJ, Wu J, Bian HL, Zong Y, Lu B, Ni L. A Comprehensive Prognostic and Immune Infiltration Analysis of RBM4 in Pan-Cancer. Frontiers in Bioscience-Landmark. 2024;29(2). doi:10.31083/j.fbl2902089

BibTeX
@article{Ding2024,
  author = {Ding, Jia-Jun and Wu, Jie and Bian, Hai-Lei and Zong, Yi and Lu, Bing and Ni, Li},
  title = {A Comprehensive Prognostic and Immune Infiltration Analysis of RBM4 in Pan-Cancer},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  volume = {29},
  number = {2},
  doi = {10.31083/j.fbl2902089}
}
Kostenlos starten →